Novartis raises full-year sales outlook after strong Q1 performance
- Novartis reported a 15% increase in net sales for the first quarter of 2025, significantly exceeding analyst expectations.
- The company has raised its full-year guidance, now expecting high single-digit sales growth and low double-digit core operating income growth.
- This strong performance is attributed to blockbuster drugs and a strategic focus on key markets, driving growth into the foreseeable future.
In Switzerland, Novartis, the renowned pharmaceutical company, released its first-quarter sales results on April 29, 2025. The firm reported net sales of $13.2 billion, which represented a 15% increase on a constant currency basis, surpassing analysts' expectations of $13.12 billion. The adjusted core operating income also performed well, climbing by 27% to $5.58 billion compared to the anticipated $5.07 billion. Positive sales were attributed mainly to the popularity of Novartis' flagship heart-failure drug, Entresto, and its arthritis treatment, Cosentyx. Notably, increasing demand for other key medications, including Kisqali for breast cancer, Kesimpta for multiple sclerosis, and Leqvio for cholesterol management, was highlighted by CEO Vas Narasimhan. He expressed confidence in the growth potential of these priority brands and their contribution to the company's future performance.